Lundbeck brings third Parkinson’s drug into clinic
August 07, 2018 / Richard Staines
Denmark’s Lundbeck is bringing a third potential drug for Parkinson’s disease to the clinic – a human antibody that the company hopes will tackle the underlying cause of the condition. The compound known as Lu AF82422 was invented by Lundbeck in collaboration with Genmab, the company that also developed Janssen’s blood cancer drug Darzalex (daratumumab). According to Lundbeck Lu AF82422 is a human antibody targeting the toxic proteins causing the death of the dopamine-producing brain cells that leads to Parkinson’s disease. The compound is thought to work like the body’s natural antibodies when the immune system works to remove harmful proteins.